We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
PSA and PSA Kinetics as Predictors for 18F-Fluciclovine PET/CT Positivity in Biochemically Recurrent Prostate Cancer.
- Authors
Crocerossa, Fabio; Carbonara, Umberto; Parekh, Jayashree; Urdaneta, Alfredo; Weprin, Samuel; Damiano, Rocco; Grob, Mayer B.; Hampton, Lance J.; Paul, Asit; Autorino, Riccardo; Cantiello, Francesco
- Abstract
Introduction: 18F-Fluciclovine PET/CT is one of the imaging techniques currently employed to restage prostate cancer (PCa). Due to the conflicting results reported in the literature, it is not yet known at what PSA threshold 18F-fluciclovine PET/CT could reliably demonstrate the presence of recurring disease. We explored the association between 18F-fluciclovine PET/CT positivity and prescan PSA, PSA doubling time, and PSA velocity in patients with biochemical recurrence (BCR) of PCa after curative-intent treatment. Methods: Data from 59 patients who underwent 18F-fluciclovine PET/CT for BCR after radical prostatectomy or radiotherapy were retrieved from a single institution database. Patients already undergone salvage treatments at the time of PET/CT, with newly diagnosed PCa or with initial diagnosis of metastatic PCa were excluded. A 2-sided independent samples Bayesian t test and Bayesian Mann-Whitney U test were used to assess the association between PET/CT and prescan PSA, PSA doubling time, and PSA velocity. Results: Evidence for no difference between PET/CT-positive and -negative patients for log-transformed PSA was found (BF01 3.61, % error: 0.01). Robustness check and sequential analysis showed stability across a wide range of prior distribution specifications. The hypothesis of no difference in terms of PSA-dt and for PSA-vel between groups was found to be more likely compared to the alternative hypothesis (BF01 of 3.44 and 3.48, respectively). Conclusion: PSA and PSA kinetics are unlikely to be associated with 18F-fluciclovine PET/CT positivity in patients with BCR, and none of these serum biomarkers might be used as single predictors of PET/CT detection. Larger studies might be needed to evaluate the role of different predictors.
- Subjects
PROSTATE cancer; PROSTATE-specific antigen; MANN Whitney U Test; SEQUENTIAL analysis; RADICAL prostatectomy; OPTIMISM
- Publication
Urologia Internationalis, 2022, Vol 106, Issue 9, p920
- ISSN
0042-1138
- Publication type
Article
- DOI
10.1159/000520684